# Integrative Omics Analysis Reveals the Potential Value of CEACAM6 in Pan‐Gastrointestinal Cancers

**Authors:** Liying Jin, Changjuan Tao, Zhiyong Pan, Peng Zhang

PMC · DOI: 10.1002/iid3.70327 · 2026-02-04

## TL;DR

This study explores how CEACAM6, a cell adhesion molecule, is overexpressed in various gastrointestinal cancers and may influence tumor growth and immune response.

## Contribution

The study is the first to investigate CEACAM6's role in pan-gastrointestinal cancers using multi-omics data and spatial transcriptomics.

## Key findings

- CEACAM6 is overexpressed in pan-gastrointestinal cancers and is linked to poor survival and immune-excluded tumor subtypes.
- CEACAM6 expression is negatively correlated with CD4+ Th1 cells and plasma cells in the tumor microenvironment.
- Spatial transcriptomics shows CEACAM6 is highly expressed in malignant regions and correlates with tumor progression.

## Abstract

Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) is known as a cell adhesion receptor which could regulate proliferation and other signaling in cancer. The role of CEACAM6 in pan‐gastrointestinal cancers remains largely uncharacterized. This study employed multi‐omics bioinformatics to investigate the expression distribution, prognostic value, and immune function of CEACAM6 in these malignancies.

Utilizing multi‐omics data from The Cancer Genome Atlas (TCGA), cBioPortal, GDSC2, TIMER2.0, and TISCH databases, we assessed the CEACAM6 expression and prognostic value across pan‐gastrointestinal cancers. Additionally, the potential role of CEACAM6 in the tumor immune microenvironment was explored using multi‐omics data, including spatial transcriptomics data.

Based on TCGA data, CEACAM6 was found to be overexpressed in pan‐gastrointestinal cancers. The CEACAM6 somatic copy number alterations, DNA methylation and mutation sites were identified as potential contributors to abnormal CEACAM6 expression. The CEACAM6 expression was significantly negatively associated with the abundance of CD4 + Th1 cells across pan‐gastrointestinal cancers. Furthermore, spatial transcriptomics data revealed that CEACAM6 expression was significant positively associated with malignant cells, while there was a negative correlation was observed with between CEACAM6 expression and plasma cells.

CEACAM6 exhibits high diagnostic accuracy and tumor‐specific overexpression in pan‐gastrointestinal cancers. CEACAM6 could promote angiogenesis/metastasis and suppress anti‐tumor immunity. Spatially localized in tumors with immune cell exclusion, CEACAM6 correlates with poor survival and immune‐excluded subtypes, positioning it as a therapeutic target in precision immunotherapy for pan‐gastrointestinal cancers.

Expression of CEACAM6 in spatial transcriptomic of colorectal cancer with liver metastases. (A) Predicted cell types mapping on colorectal cancer tissue slice; (B) Spatial distribution of CEACAM6; (C) Spatial distribution of malignant region, mixed region and normal region; (D) The difference expression of CEACAM6 in malignant region, mixed region and normal region; (E) The correlation heatmap between CEACAM6 expression and different cell types.

## Linked entities

- **Genes:** CEACAM6 (CEA cell adhesion molecule 6) [NCBI Gene 4680]
- **Diseases:** colorectal cancer (MONDO:0005575)

## Full-text entities

- **Genes:** PATZ1 (POZ/BTB and AT hook containing zinc finger 1) [NCBI Gene 23598] {aka MAZR, PATZ, RIAZ, ZBTB19, ZNF278, ZSG}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, GZMB (granzyme B) [NCBI Gene 3002] {aka C11, CCPI, CGL-1, CGL1, CSP-B, CSPB}, SP1 (Sp1 transcription factor) [NCBI Gene 6667], MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, SP2 (Sp2 transcription factor) [NCBI Gene 6668], DNER (delta/notch like EGF repeat containing) [NCBI Gene 92737] {aka UNQ26, bet}, CEACAM6 (CEA cell adhesion molecule 6) [NCBI Gene 4680] {aka CD66c, CEAL, NCA, NCA-50/90}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, SMAD3 (SMAD family member 3) [NCBI Gene 4088] {aka HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, KLF12 (KLF transcription factor 12) [NCBI Gene 11278] {aka AP-2rep, AP2REP, HSPC122}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, SP4 (Sp4 transcription factor) [NCBI Gene 6671] {aka HF1B, SPR-1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, CD4 (CD4 molecule) [NCBI Gene 395362], KLF5 (KLF transcription factor 5) [NCBI Gene 688] {aka BTEB2, CKLF, IKLF}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, EGFR (epidermal growth factor receptor) [NCBI Gene 396494] {aka c-erbB}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, TCF4 (transcription factor 4) [NCBI Gene 6925] {aka CDG2T, E2-2, FCD2, FECD3, ITF-2, ITF2}, SP3 (Sp3 transcription factor) [NCBI Gene 6670] {aka SPR2}, TSC1 (TSC complex subunit 1) [NCBI Gene 7248] {aka LAM, TSC}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, HAVCR2 (hepatitis A virus cellular receptor 2) [NCBI Gene 84868] {aka CD366, HAVcr-2, KIM-3, SPTCL, TIM3, TIMD-3}, KDM5B (lysine demethylase 5B) [NCBI Gene 10765] {aka CT31, JARID1B, MRT65, PLU-1, PLU1, PPP1R98}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747] {aka FADK, FADK 1, FAK, FAK1, FRNK, PPP1R71}
- **Diseases:** COAD (MESH:D029424), liver metastases (MESH:D009362), hypoxia (MESH:D000860), anal cancer (MESH:D001005), pancreatic intraepithelial neoplasia (MESH:D002578), precancerous gastric lesions (MESH:D011230), MSI-H (MESH:D053842), inflammation (MESH:D007249), adenocarcinoma (MESH:D000230), cancer (MESH:D009369), pancreatic cancer (MESH:D010190), cytotoxicity (MESH:D064420), Pan-gastrointestinal malignancies (MESH:C537931), ESCA (MESH:D004938), aneuploidy (MESH:D000782), gastric dysplasia (MESH:D013272), colon cancer (MESH:D015179), Pan-Gastrointestinal Cancer (MESH:D005770), carcinogenesis (MESH:D063646), gastric cancer (MESH:D013274), microbial infection (MESH:D015163), rectum cancer (MESH:D012004), tumorigenic (MESH:D002471)
- **Chemicals:** l-DOS47 (-), lipid (MESH:D008055)
- **Species:** Helicobacter pylori (species) [taxon 210], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** initiation site to 3000
- **Cell lines:** TOP200 — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_TT29), DT40 B — Gallus gallus (Chicken), Chicken bursal lymphoma, Cancer cell line (CVCL_0249)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12872969/full.md

---
Source: https://tomesphere.com/paper/PMC12872969